Thyroid Cancer research at endocrinology and metabolism research institute (EMRI): a report of scientific activities between 2005 and 2020-Reference-Cited by-同舟云学术

Thyroid Cancer research at endocrinology and metabolism research institute (EMRI): a report of scientific activities between 2005 and 2020

Published:2021-01-07 Issue: Volume: Page:
ISSN:2251-6581
Container-title:Journal of Diabetes & Metabolic Disorders
language:en
Short-container-title:J Diabetes Metab Disord

Author:

Samimi Hilda,Shirzad Nooshin,Sajjadi-Jazi Sayed Mahmoud,Heshmat Ramin,Amoli Mahsa M,Mohajeri-Tehrani Mohammad Reza,Tavangar Seyed Mohammad,Larijani Bagher,Haghpanah Vahid^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40200-020-00702-1.pdf

Reference56 articles.

1. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA, Sigurdson AJ, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99(2):E276–E85.

2. Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid Cancer. Eur Thyroid J. 2019;8(5):227–45.

3. Aashiq M, Silverman DA, Na’ara S, Takahashi H, Amit M. Radioiodine-refractory thyroid Cancer: molecular basis of Redifferentiation therapies, management, and novel therapies. Cancers. 2019;11(9):1382.

4. Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin. 2013;63(6):373–94.

5. Larijani B, Mohagheghi MA, Bastanhagh MH, Mosavi-Jarrahi AR, Haghpanah V, Tavangar SM, et al. Primary thyroid malignancies in Tehran, Iran. Med Princ Pract. 2005;14(6):396–400.